In vivo imaging of human cerebral acetylcholinesterase

Journal of Neurochemistry

Volumn 67, Issue 2, 1996, Pages 876-879

  Pappata, S ^a,b   Tavitian, B ^a,b   Traykov, L ^a   Jobert, A ^a   Dalger, A ^a   Mangin, J F ^b   Crouzel, C ^b   Di Giamberardino, L ^a  

^a INSERM   (France)

^b DIF   (France)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Human brain; Neurodegenerative disorders; Physostigmine; Positron emission tomography

Indexed keywords

ACETYLCHOLINESTERASE; BRAIN ENZYME; CARBON 11; CHOLINESTERASE INHIBITOR; PHYSOSTIGMINE;

ADULT; AGED; ARTICLE; BRAIN REGION; ENZYME ANALYSIS; ENZYME LOCALIZATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; VOLUNTEER;

EID: 0030017317     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.67020876.x     Document Type: Article

References (24)

1. Becker R. E. and Giacobini E. (1988) Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects. Drug Dev. Res. 12, 163-195.
2. 11C-physostigmine. J. Label. Comp. Radiopharm. 33, 277-284.
3. Brimijoin S. and Hammond P. (1988) Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay. J. Neurochem. 51, 1227-1231.
4. Davies P. (1979) Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 171, 319-327.
5. Dawson R. M. (1994) Rate constants of carbamylation and decarbamylation of acetylcholinesterase for physostigmine and carbaryl in the presence of an oxime. Neurochem. Int. 24, 173-182.
6. Finkelstein Y., Wolff M., and Biegon A. (1988) Brain acetylcholinesterase after acute Parathion poisoning: a comparative quantitative histochemical analysis post mortem. Ann. Neurol. 24, 252-257.
7. Geula C. and Mesulam M. M. (1994) Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, in Alzheimer Disease (Terry R. D., Katzman R., and Bick K. L., eds), pp. 263-287. Raven Press, New York.
8. Green R. C., Blume H. W., Kupferschmid S. B., and Mesulam M. M. (1989) Alterations of hippocampal acetylcholinesterase in human temporal lobe epilepsy. Ann. Neurol. 26, 347-351.
9. Greig N. H., Pei X. F., Soncrant T. T., Ingram D. K., and Brossi A. (1995) Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med. Res. Rev. 15, 3-31.
10. Hammond P. and Brimijoin S. (1988) Acetylcholinesterase in Huntington's and Alzheimer's diseases: simultaneous enzyme assay and immunoassay of multiple brain regions. J. Neurochem. 50, 1111-1116.
11. Huff F. J., Reiter C. T., and Rand J. B. (1988) The ratio of acetylcholinesterase to butyrylcholinesterase influences the specificity of assays for each enzyme in human brain. J. Neural Transm. 75, 129-134.
12. Irie T., Fukushi K., Akimoto Y., Tamagami H., and Nozaki T. (1994) Design and evaluation of radioactive acetylcholine analogs for mapping brain acetycholinesterase (AChE) in vivo. Nucl. Med. Biol. 21, 801-808.
13. Kataoka K., Hayakawa T., Ryotaro R., Yuguchi T., and Yamada K. (1991) Cholinergic deafferentation after focal cerebral infarct in rats. Stroke 22, 1291-1296.
14. Kilbourn M. R., Snyder S. E., Sherman P. S., and Kuhl D. E. (1996) In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[C-11]methylpiperdin-4-yl propionate ([C-11]-PMP). Synapse 22, 123-131.
15. Kish S. J., Schut L., Simmons J., Gilbert J., Chang L. J., and Rebbetoy M. (1988) Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy. J. Neurol Neurosurg. Psychiatry 51, 544-548.
16. Loewenstein-Lichtenstein Y., Schwarz M., Glick D., Nordgaard-Pedersen B., Zakut H., and Soreq H. (1995) Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BCHE carriers. Nature Med. 1, 1082-1085.
17. Mangin J. F., Frouin V., Bloch I., Bendriem B., and Lopez-Krahe J. (1994) Fast nonsupervised 3D registration of PET and MR images of the brain. J. Cereb. Blood Flow Metab. 14, 749-762.
18. Mesulam M. M., Geula C., and Moran M. A. (1987) Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann. Neurol. 22, 683-691.
19. Namba H., Irie T., Fukushi K., and Iyo M. (1994) In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. Brain Res. 667, 278-282.
20. 11C-physostigmine. Neuroimage 1, 173-180.
21. Ruberg M., Rieger F., Villageois A., Bonnet A. M., and Agid Y. (1986) Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and nondemented patients with Parkinson's disease. Brain Res. 362, 83-91.
22. Talairach J. and Tournaux P. (1988) Co-Planar Stereotaxic Atlas of the Human Brain. Thieme, New York.
23. Tavitian B., Pappata S., Planas A. M., Jobert A., Bonnot Lours S., Crouzel C., and Di Giamberardino L. (1993) In vivo visualization of acetylcholinesterase with positron emission tomography. Neuroreport 4, 535-538.
24. 11C] physostigmine, a PET tracer for acetylcholinesterase. (Abstr.) J. Cereb. Blood Flow Metab. 15 (Suppl.), S122.